Status:
COMPLETED
Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
Lead Sponsor:
Finnish Institute for Health and Welfare
Collaborating Sponsors:
Turku University Hospital
GlaxoSmithKline
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
13-3 years
Brief Summary
The aim of the study are to assess the persistence of immunity against vaccine serotypes (VSTs) and vaccine-related serotypes in PCV10 vaccinated children in Finland.
Detailed Description
The primary objective is to evaluate the long-term persistence of humoral immunity to vaccine-related pneumococcal serotypes after vaccination with PCV10.
Eligibility Criteria
Inclusion
- Completed PCV10 vaccination with 3 or 4 doses (2+1 or 3+1 schedule) before blood sampling at age of 13 months
- Age at sample collection 13 months, 2 years or 3 years
- PCV10 vaccination received 2-6 weeks before sample collection at the age of 1 year
- Informed consent obtained covering the planned analyses
Exclusion
- PCV13 or PPV23 dose received
- Informed consent withdrawn
Key Trial Info
Start Date :
November 12 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 7 2013
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT04912297
Start Date
November 12 2009
End Date
May 7 2013
Last Update
August 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Finnish Institute for Health and Welfare
Helsinki, Finland